Michael T. Zvarich

Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee

Lorcan McGarvey, M. Knight John, J. Anderson et al. · Thorax · 2007 · 559 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +16

Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: Results of a 24-week, randomized, controlled trial

M. Reza Maleki-Yazdi, Thomas Kaelin, Nathalie Richard et al. · Respiratory Medicine · 2014 · 122 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Accuracy of Death Certificates in COPD: Analysis from the TORCH Trial

Michael Drummond, Robert A. Wise, Matthias John et al. · COPD Journal of Chronic Obstructive Pulmonary Disease · 2010 · 58 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +17

A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD

Àlvar Agustí, Luis de Teresa, Wilfried De Backer et al. · European Respiratory Journal · 2013 · 51 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Effect of Once-Daily Fluticasone Furoate/Vilanterol on 24-Hour Pulmonary Function in Patients With Chronic Obstructive Pulmonary Disease: A Randomized, Three-Way, Incomplete Block, Crossover Study

Joseph Boscia, Krishna Pudi, Michael T. Zvarich et al. · Clinical Therapeutics · 2012 · 48 citations

Medicine, Pharmacology, Pharmacotherapy +17